New drug price controversy looms as Biogen stuns payers with Spinraza's $750K sticker — analyst
One prominent analyst believes we may soon see a new drug price controversy erupt, only this one will have nothing to do with price gouging on an old therapy.
The drug is Spinraza, the newly approved pioneering therapy for rare cases of spinal muscular atrophy from Biogen and its partners at Ionis. Earlier this week Biogen priced the drug at about $750,000 for the first year and half that for each year after, or $1.5 million over three years.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters